BLOG

In Conversation: NantKwest — Harnessing Natural Killer Cells to Treat Cancer

Effectively harnessing the immune system requires activation of natural killer, dendritic, and T cells. NantKwest is developing off-the-shelf therapies that have shown great promise in initial clinical studies. Emilie Branch, editor at Pharma’s Almanac, sat down with NantKwest’s Chairman and CEO, Dr. Patrick Soon-Shiong, to discuss this exciting treatment option and find out why it could be one of the most promising developments in oncology to date.